Fig. 3.
Kaplan‐Meier analysis of clinical outcomes for patients with metastatic renal cell carcinoma starting 1L systemic treatments. (A) Time on treatment. (B) Time to next treatment. (C) Overall survival. 1L = first-line; Axi = axitinib; CI = confidence interval; Ipi = ipilimumab; Nivo = nivolumab; NR = not reached; Pembro = pembrolizumab; TKI = tyrosine kinase inhibitor.